Dasatinib-induced immune mediated-thrombotic thrombocytopenic purpura

Demirsoy E. T., MEHTAP Ö., Atesoglu E. B., TARKUN P., EREN N., Geduk A., ...Daha Fazla

TRANSFUSION AND APHERESIS SCIENCE, cilt.57, sa.2, ss.222-224, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 57 Sayı: 2
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.transci.2018.02.003
  • Dergi Adı: TRANSFUSION AND APHERESIS SCIENCE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.222-224
  • Anahtar Kelimeler: Dasatinib, Thrombotic thromboytopenic purpura, Plasma exchange, Side effect, PATHOGENESIS, LEUKEMIA
  • Kocaeli Üniversitesi Adresli: Evet

Özet

Most commonly seen side effects with Tyrosine kinase inhibitors (TKI's) are hematologic toxicities. Besides, with dasatinib autoimmune side effects can be seen. Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease that can be related to various causes mainly autoimmune disorders or antineoplastic drugs. Few cases of TKI associated secondary thrombotic microangiopathies (TMA) have been reported in literature. Most of cases were diagnosed as hemolytic uremic syndrome (HUS) rather than TTP. Herein, we describe a 37-year-old CML patient who was diagnosed as immune-mediated TTP related to dasatinib. (C) 2018 Elsevier Ltd. All rights reserved.